Lpath, Inc.

Vaxiion Therapeutics, LLC

Medlyte Diagnostics, Inc.

Lpath Therapeutics, Inc.

Medlyte, Inc., Sdsu Heart Institute

Medlyte, Inc.

Roger A Sabbadini

William A Garland

Genevieve Hansen

Mark William Surber

Neil Berkley

Steven Tarran Jones

David Gareth Williams

Robert Klepper

Glenn L Stoller

Rosalia Matteo

James Stephen Swaney

Jonathan Michael Wojciak

Gordon B Mills

Matthew J Giacalone

Scott R Pancoast

Marina Safonov

Amy L Cavalli

Tom Huxford

Minicells are used to deliver biologically active compounds including radioisotopes, polypeptides, nucleic acids, small molecules, drug molecules, and chemotherapeutic agents. In some cases, the minicell displays ligands or binding moieties that target the minicell to a desired host cell.

Minicell based delivery of biologically active compounds

Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.

Methods and reagents for detecting bioactive lipids

Methods for preventing or treating pain are provided. Such methods comprise administering to a subject (e.g., a human subject) an antibody or antibody fragment that binds LPA. The antibody may be a humanized monoclonal antibody.

Prevention and treatment of pain using antibodies to lysophosphatidic acid

Immune-derived moieties reactive against lysophosphatidic acid

The present invention relates to compositions that comprise an anti-S1P monoclonal antibody, antibody fragment, or derivative in a carrier, particularly a buffered, hypertonic aqueous solution, as well as to kits containing such compositions, and methods for using such compositions for treatment of diseases and conditions associated with S1P.

Pharmaceutical compositions for binding sphingosine-1-phosphate

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Compositions and methods for binding lysophosphatidic acid

The present invention relates to use of anti-S1P agents, for example, humanized monoclonal antibodies, for prevention and/or treatment of pain, including neuropathic pain, hyperalgesia, allodynia, and chemotherapy-induced pain.

Prevention and treatment of pain using antibodies to sphingosine-1-phosphate

Bioactive lipid derivatives, and methods of making and using same

The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.

Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions

Compositions and methods for making and using humanized anti-LPA monoclonal antibodies, and fragments and derivatives thereof, are described.

Humanized antibody compositions and methods for binding lysophosphatidic acid

The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

Immunogenic minicells and methods of use

Compositions and methods for treating ocular diseases and conditions

Methods for designing optimized antibodies, including optimized humainized or human antibodies, to target bioactive lipids are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided, as are methods for using them.

Antibody design using anti-lipid antibody crystal structures

The present invention relates to use of anti-S1P antibodies in combination with chemotherapeutic agents for treatment and/or prevention of cancer, tumor growth, metastasis and/or growth of metastatic tumors.

Growing community of inventors

Lakeside, CA, United States of America

Roger A Sabbadini